相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Sergio Martinez-Hoyer et al.
NATURE CELL BIOLOGY (2020)
MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways
Minyoung Youn et al.
BLOOD ADVANCES (2019)
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Laurent Garderet et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Vincent Chung et al.
CLINICAL CANCER RESEARCH (2017)
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Naoko Hosono et al.
ONCOTARGET (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The 5q Deletion Size in Myeloid Malignancies Is Correlated to Additional Chromosomal Aberrations and to TP53 Mutations
Anna Stengel et al.
GENES CHROMOSOMES & CANCER (2016)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
M. Mossner et al.
LEUKEMIA (2016)
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K. Schneider et al.
NATURE MEDICINE (2016)
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms
Chantana Polprasert et al.
CANCER CELL (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Rebekka K. Schneider et al.
CANCER CELL (2014)
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A. F. List et al.
LEUKEMIA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion
David P. Steensma et al.
BLOOD (2013)
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
U. Platzbecker et al.
LEUKEMIA (2013)
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
S. Wei et al.
ONCOGENE (2013)
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Gisela Caceres et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
L-leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway
Elspeth M. Payne et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Cancer Vulnerabilities Unveiled by Genomic Loss
Deepak Nijhawan et al.
CELL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
Andres Jerez et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A. Sekeres et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Genetic deletions in AML and MDS
Benjamin L. Ebert
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
Pellegrino Musto et al.
CANCER (2010)
WHO-defined 'myelodysplastic syndrome with isolated del(5q)′ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
M. M. Patnaik et al.
LEUKEMIA (2010)
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome
Jillian L. Barlow et al.
NATURE MEDICINE (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Ramin Tehranchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Martin Jadersten et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q
D. Chen et al.
LEUKEMIA (2009)
Absence of nucleolar disruption after impairment of 40s ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction
Stefano Fumagalli et al.
NATURE CELL BIOLOGY (2009)
Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis
Timothy A. Graubert et al.
PLOS ONE (2009)
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era
Shernan G. Holtan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
Chromosomal abnormalities in cancer
Stefan Froehling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Benjamin L. Ebert et al.
PLOS MEDICINE (2008)
The molecular signature of MDS stem cells supports a stem-cell origin of 5q -: myelodysplastic syndromes
Lars Nilsson et al.
BLOOD (2007)
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
Magda Melchert et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Treatment of deletion 5q acute myeloid leukemia with lenalidomide
J. E. Lancet et al.
LEUKEMIA (2007)
The impact of translocations and gene fusions on cancer causation
Felix Mitelman et al.
NATURE REVIEWS CANCER (2007)
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5) (q13q33) myelodysplastic syndrome
R. A. Mesa et al.
LEUKEMIA (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile
C Schoch et al.
GENES CHROMOSOMES & CANCER (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
AAN Giagounidis et al.
LEUKEMIA (2004)
Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome
J Boultwood et al.
BLOOD (2002)
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
D Grimwade et al.
BLOOD (2001)
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
A Raza et al.
BLOOD (2001)
Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease
C Soncini et al.
ONCOGENE (2001)
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)
F Lai et al.
GENOMICS (2001)
分享论文
